Strong Q1 prompts an improved guidance
05/05/21 -"2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this momentum to be maintained, the 2021 outlook has ..."
Pages
68
Language
English
Published on
05/05/21
You may also be interested by these reports :
24/08/26
Q2 profitability beat expectations; however, the top line lagged consensus. The quarterly growth was driven by strong performance in LatAm, Animal ...
21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...
21/08/26
Siegfried delivered a strong set of results in 1H26. Net sales grew by +2.2% YoY (+4.8% in LC), largely supported by the additional revenues ...
21/08/26
Moderna’s mRNA cancer vaccine combined with Merck’s Keytruda does look like a game changer for the wider pharma industry. It looks like a decisive ...